Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
06/11/26	¥266.00	-5.34%	63,700
05/11/26	¥281.00	-5.70%	89,400
04/11/26	¥298.00	+1.02%	72,300
02/11/26	¥295.00	-1.99%	26,600
30/10/26	¥301.00	+1.01%	51,400

Delayed Quote Japan Exchange

More quotes

Market Closed - Japan Exchange 09:30:00 06/11/2026 +03			5-day change	1st Jan Change
266.00 ^JPY	-5.34%		-11.63%	-44.58%

11-02	Veritas In Silico Inc. And Syntara Limited Sign Memorandum Of Understanding To Accelerate Joint Discovery Research For mRNA-Targeted Compounds	CI
10-29	Veritas In Silico Inc. announced that it has received ¥2.801 million in funding	CI

Market Cap	1.73B 10.9M 9.77M 8.93M 8.15M 15.36M 1.02B 15.85M 108M 42.93M 547M 40.9M 40.03M	P/E 2024	-23.8x	P/E 2025	-7.32x
Enterprise Value	-99.64M -629K -564K -516K -471K -887K -59.15M -915K -6.22M -2.48M -31.56M -2.36M -2.31M	EV / Sales 2024	18.2x	EV / Sales 2025	14.1x
Free-Float	45.01%	Yield 2024 *	-	Yield 2025	-

11-02	Veritas In Silico Inc. And Syntara Limited Sign Memorandum Of Understanding To Accelerate Joint Discovery Research For mRNA-Targeted Compounds	CI
10-29	Veritas In Silico Inc. announced that it has received ¥2.801 million in funding	CI
10-20	Veritas In Silico Identifies Hit Compounds in Toray Collaboration	MT
10-13	Veritas In Silico Inc. announced that it expects to receive ¥2.801 million in funding	CI
08-05	Veritas In Silico Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-04	Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug	MT
05-11	SpiroChem AG and Veritas in Silico Inc. Enter Joint Research Agreement to Initiate Discovery of Next Generation mRNA Binding Chemical Matter	CI
04-13	Veritas In Silico and Takeda Mutually Terminate mRNA-Targeted Drug Research Collaboration	MT
04-13	Veritas in Silico Inc. Terminates Collaborative Drug Discovery Research with Takeda Pharmaceutical Company Limited	CI
02-12	Veritas in Silico Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026	CI
02-12	Veritas In Silico Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-26	SpiroChem AG and Veritas In Silico Inc. Sign MoU to Accelerate Discovery of Next Generation RNA Binding Chemical Matter	CI
01-19	The Jikei University School of Medicine and Veritas In Silico Inc. Announce Patent Publication for Novel Nucleic Acid Therapeutic Targeting Amyotrophic Lateral Sclerosis	CI

1 day	-5.34%
1 week	-11.63%
Current month	-11.63%
1 month	-38.28%
3 months	-34.00%
6 months	-42.80%
Current year	-44.58%

Veritas In Silico Inc. Stock

Stocks

130A

JP3155340007

Biotechnology & Medical Research

Valuation: Veritas In Silico Inc.

Chart: Veritas In Silico Inc.

Latest news: Veritas In Silico Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Veritas In Silico Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Shingo Nakamura CEO	Chief Executive Officer	54	17/11/2016
Hiroaki Hagiwara DFI	Director of Finance/CFO	57	01/01/2022
Isao Koda PRN	Corporate Officer/Principal	69	01/12/2018

Director	Title	Age	Since
Shingo Nakamura BRD	Director/Board Member	54	17/11/2016
Kinichiro Kominami BRD	Director/Board Member	59	01/08/2019
Hiroaki Hagiwara BRD	Director/Board Member	57	01/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VERITAS IN SILICO INC.	-5.34%	-11.63%	-51.64%	-	10.9M
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+63.79%	65.94B
ARGENX SE	+0.02%	+1.07%	+11.72%	+75.63%	56.88B
LONZA GROUP AG	-1.34%	+2.98%	+25.08%	+100.18%	56.53B
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+105.85%	46.49B
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+35.86%	44.8B
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+794.74%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+55.48%	35.35B
GENMAB A/S	-2.97%	-9.84%	+90.91%	+73.49%	33.29B
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+368.87%	25.1B
Average	+0.48%	+1.22%	+39.10%	+185.99%	40.6B
Weighted average by Cap.	+0.66%	+3.07%	+49.89%	+166.07%

	2024	2025
Net sales	195M 1.23M 1.1M 1.01M 920K 1.73M 116M 1.79M 12.15M 4.84M 61.66M 4.61M 4.52M	91.14M 576K 516K 472K 431K 811K 54.11M 837K 5.69M 2.27M 28.87M 2.16M 2.11M
Net income	-236M -1.49M -1.34M -1.22M -1.12M -2.11M -140M -2.17M -14.75M -5.88M -74.9M -5.6M -5.48M	-426M -2.69M -2.41M -2.2M -2.01M -3.79M -253M -3.91M -26.56M -10.59M -135M -10.09M -9.87M
Net Debt	-2.17B -13.73M -12.31M -11.25M -10.27M -19.35M -1.29B -19.96M -136M -54.07M -688M -51.52M -50.41M	-1.83B -11.53M -10.34M -9.45M -8.63M -16.25M -1.08B -16.76M -114M -45.41M -578M -43.27M -42.34M

1 week	259	325
1 month	259	431
Current year	259	586
1 year	259	793
3 years	259	3,475
5 years	259	3,475
10 years	259	3,475